Lv1
80 积分 2022-01-07 加入
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
4天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
5天前
已完结
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
1个月前
已完结
Frequent loss of heterozygosity on chromosome 6p in uveal melanoma
1个月前
已完结
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
1个月前
已完结
PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors
1个月前
已完结
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
1个月前
已完结
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
2个月前
已完结
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
2个月前
已关闭
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2个月前
已完结
皖公网安备34019202002308
